Alimera is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in their aging populations.
Alimera was founded in June 2003 by Dan Myers, Daniel White, Dave Holland and Mark Testerman. The company is based in Alpharetta, Georgia and it's European operations are conducted from London by its subsidiary, Alimera Sciences Limited.
Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases.
Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases.
Alimera is backed by leading investors including Palo Alto Investors, Polaris Partners, New Enterprise Associates, & Hercules Capital, Inc. among others.
